Abstract
Summary: A new progestational agent, medroxyprogesterone acetate (Provera), has been used in the second and third trimesters of pregnancy in an attempt to prolong gestation and thereby increase foetal salvage. Experience in 89 pregnancies has been recorded. In 21 pregnancies, cervical suture has provided supportive therapy. Sixty‐one surviving infants have resulted from 65 pregnancies in which prolongation was achieved for a significant period of time. The intravenous injection of an aqueous suspension of crystalline Provera has been used in 12 patients. On 6 occasions, where cervical dilatation was less than 3 cm., parturition was postponed. No significant side‐effect, in either mother or infant, has resulted from the use of this synthetic progestational agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Australian & New Zealand journal of obstetrics & gynaecology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
